Loading…
Employees: 172
Size 908 Devices (MASS) is a United States Health Care company (Medical Specialties) with a market value of $436M, the 2789th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.56 on 6 Nov 2026.
Performance Over six months the shares gained 29.2%, against -22.1% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 0.7% over the last twelve months (peer median +12.0%); the operating margin is -35.4% (peer median 3.6%).
Valuation It trades at 5.5× enterprise value to sales against a peer median of 5.0× (9th most expensive of 21).
Capital Return on invested capital runs 68.4 points below its cost of capital (8.1% WACC).
Backlog Backlog (remaining performance obligations) was $21.7M at 30 Jun 2026, up 21% on a year earlier — 0.4 years of trailing revenue. Backlog detail →
Short interest Short interest is 6.5% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $60.8M | $56.2M | $47.7M | $50.2M | $46.9M |
| Revenue growth | — | +18% | -5% | +7% | — |
| Gross profit | $29.7M | $26.8M | $21.5M | $23.4M | $24.6M |
| EBITDA | -$16.8M | -$19.7M | -$25.3M | -$40.0M | -$33.6M |
| Net income | -$34.5M | -$36.6M | -$72.2M | -$36.4M | -$33.6M |
| Free cash flow | $494,000 | -$24.6M | -$30.8M | -$27.1M | -$23.0M |
| Capital expenditure | $876,000 | $955,000 | $602,000 | $2.04M | $2.04M |
| Total debt | $4.30M | $4.63M | $4.07M | $5.95M | $19.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MASS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -12.7% | 10th highest of 21 |
| 6-month return | +29.2% | -22.1% | 2nd highest of 20 |
| Distance from 52-week high | -20.9% | -40.9% | 2nd highest of 21 |
| Revenue growth (TTM) | +0.7% | +12.0% | 6th lowest of 21 |
| Operating margin | -35.4% | 3.6% | 6th lowest of 21 |
| EV / Sales | 5.5× | 5.0× | 9th most expensive of 21 |
| ROIC minus cost of capital | -68.4 pp | -4.9 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | 5.5× | n/a | n/a |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | 7.8× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 1.5× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 4.4× | 11.8% | +5.6% |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | 4.5× | n/a | n/a |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | 5.7× | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 6.5× | 34.3% | +18.8% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | 410.3× | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | 8.0× | n/a | n/a |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | 704.2× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 3.7× | 0.9% | +15.6% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 1.5× | n/a | n/a |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 8.1× | 55.5% | +3.8% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | 1.6× | 23.3% | +18.1% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | 20.2× | n/a | n/a |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 5.4× | 9.8% | +3.4% |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | 1.9× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
908 Devices reported $21.7M of remaining performance obligations at 30 Jun 2026, up 21% from a year earlier and up 17% from the previous quarter. That is 0.4 years of trailing revenue already under contract. Book-to-bill last quarter: 1.20.